• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Tempus AI Inc.

    8/8/24 4:38:12 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology
    Get the next $TEM alert in real time by email
    SC 13G 1 formsc13g.htm Proof -

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

     

    Tempus AI, Inc.

    (Name of Issuer)

     

    Class A Common Stock

    (Titles of Class of Securities)

     

    71535D106

    (CUSIP Number)

     

    June 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☐ Rule 13d-1(c)

     

    ☒ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    1  

    Name of Reporting Person

     

    BK TL21 LLC

    2  

    Check the Appropriate Box if a Member of a Group

    (a) ☐ (b) ☐

     

    3  

    SEC Use Only

     

    4  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

      5  

    Sole Voting Power

     

    0

      6  

    Shared Voting Power

     

    16,560,249

      7  

    Sole Dispositive Power

     

    0

      8  

    Shared Dispositive Power

     

    16,560,249

    9  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    16,560,249

    10  

    Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    ☐

    11  

    Percent of Class Represented by Amount in Row 9

     

    11.1%1

    12  

    Type of Reporting Person

     

    CO

     

     

    1 Based on 149,274,923 shares outstanding as reported the issuer’s Form 10-Q for the quarterly period ended June 30, 2024 filed with the SEC on August 6, 2024.

     

     
     

     

    1  

    Name of Reporting Person

     

    Bradley Keywell

    2  

    Check the Appropriate Box if a Member of a Group

    (a) ☐ (b) ☐

     

    3  

    SEC Use Only

     

    4  

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

      5  

    Sole Voting Power

     

    16,560,249

      6  

    Shared Voting Power

     

    0

      7  

    Sole Dispositive Power

     

    0

      8  

    Shared Dispositive Power

     

    16,560,249

    9  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    16,560,249

    10  

    Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    ☐

    11  

    Percent of Class Represented by Amount in Row 9

     

    11.1%2

    12  

    Type of Reporting Person

     

    IN

     

     

    2 Based on 149,274,923 shares outstanding as reported the issuer’s Form 10-Q for the quarterly period ended June 30, 2024 filed with the SEC on August 6, 2024.

     

     
     

     

    Item 1(a). Name of Issuer:

     

    Tempus AI, Inc.

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    600 West Chicago Avenue, Suite 510

     

    Chicago, Illinois 60654

     

    Item 2(a). Name of Person Filing:

     

    This Schedule 13G is being filed by the following persons (each, a “Reporting Person”):

     

    i. BK TL21 LLC (“BK”)

     

    ii. Bradley Keywell (“Keywell”)

     

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     

    The principal business address of each of the Reporting Persons is:

     

    4603 Franklin Pike

     

    Nashville, Tennessee 37220

     

    Item 2(c). Citizenship:

     

    BK is organized under the laws of the State of Delaware.

     

    Keywell is a citizen of the United States.

     

    Item 2(d). Titles of Classes of Securities:

     

    Class A Common Stock, par value $0.0001 per share (the “Shares”).

     

    Item 2(e). CUSIP Number:

     

    71535D106

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4. Ownership

     

    (a) Amount beneficially owned:

     

    See response to Item 9 on each Reporting Person’s cover page.

     

    (b) Percent of class:

     

    See response to Item 11 on Reporting Person’s cover page.

     

    (c) Number of shares as to which such person has:

     

    (i) Sole power to vote or to direct the vote:

     

    See response to Item 5 on each Reporting Person’s cover page.

     

     
     

     

    (ii) Shared power to vote or to direct the vote:

     

    See response to Item 6 on each Reporting Person’s cover page.

     

    (iii) Sole power to dispose or to direct the disposition of:

     

    See response to Item 7 on each Reporting Person’s cover page.

     

    (iv) Shared power to dispose or to direct the disposition of:

     

    See response to Item 8 on each Reporting Person’s cover page.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a–11.

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: August 8, 2024

     

      BK TL21 LLC.
         
      By: /s/ Bradley Keywell
      Name:  Bradley Keywell
      Title: Manager

     

      /s/ Bradley Keywell
      Bradley Keywell

     

     

     

    Get the next $TEM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TEM

    DatePrice TargetRatingAnalyst
    4/21/2025$60.00Buy
    BTIG Research
    2/25/2025$50.00 → $55.00Overweight → Neutral
    Analyst
    2/12/2025Outperform → Mkt Perform
    William Blair
    2/5/2025$58.00 → $74.00Buy
    TD Cowen
    12/13/2024$60.00Outperform
    Wolfe Research
    12/9/2024$74.00Buy
    Guggenheim
    11/11/2024$45.00 → $65.00Buy → Hold
    Stifel
    10/2/2024$45.00 → $60.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $TEM
    SEC Filings

    View All

    SEC Form 144 filed by Tempus AI Inc.

    144 - Tempus AI, Inc. (0001717115) (Subject)

    8/20/25 7:14:37 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form DEF 14C filed by Tempus AI Inc.

    DEF 14C - Tempus AI, Inc. (0001717115) (Filer)

    8/18/25 4:10:45 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form 144 filed by Tempus AI Inc.

    144 - Tempus AI, Inc. (0001717115) (Subject)

    8/18/25 2:44:00 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tempus Announces the Acquisition of Paige

    Paige's strong foundation in pathology and AI is rooted in its proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in digital pathology with an industry leading technology portfolio. Founded in 2017, Paige has developed and deployed several AI applications, including the first FDA-cleared AI application in pathology, allowin

    8/22/25 9:20:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus Reports Second Quarter 2025 Results

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended June 30, 2025. Revenue increased 89.6% year-over-year to $314.6 million in the second quarter Genomics revenue increased 115.3% year-over-year to $241.8 million on accelerating year-over-year volume growth in Oncology (26%) and Hereditary (32%) testing Data and services revenue increased 35.7% year-over-year to $72.8 million, led by Insights (data licensing), which grew 40.7% year-over-year Quarterly gross profit was $195.0 million, a 158.3% year-over-year increase Issued $750 million of 0.75% conv

    8/8/25 6:00:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity

    MarketNewsUpdates News Commentary NEW YORK, July 22, 2025 /PRNewswire/ -- According to a report from Research And Markets, the AI in Ophthalmology Market was valued at USD 209.23 million in 2024, and is projected to reach USD 1.36 billion by 2030, rising at a CAGR of 36.79%. The rising prevalence of eye diseases, advancements in imaging technology, and expansion of teleophthalmology services are factors contributing to market growth.  The report said: "In addition, growing preference for personalized treatment plans and increasing government initiatives fuel market growth further. The increasing prevalence of eye-related conditions, such as diabetic retinopathy, age-related macular degenerat

    7/22/25 8:45:00 AM ET
    $ALC
    $BLCO
    $JNJ
    Ophthalmic Goods
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Computer Software: Programming Data Processing

    $TEM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tempus Ai, Inc. exercised 9,218,800 in-the-money shares at a strike of $2.00 and bought $17,745,000 worth of shares (3,500,000 units at $5.07) (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Reporting)

    8/20/24 4:17:55 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Tempus AI Inc.

    SC 13G - Tempus AI, Inc. (0001717115) (Subject)

    11/12/24 5:00:02 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form SC 13G filed by Tempus AI Inc.

    SC 13G - Tempus AI, Inc. (0001717115) (Subject)

    11/12/24 4:30:28 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SC 13D/A filed by Tempus AI Inc.

    SC 13D/A - Tempus AI, Inc. (0001717115) (Filed by)

    8/20/24 4:27:51 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Financials

    Live finance-specific insights

    View All

    Tempus Announces the Acquisition of Paige

    Paige's strong foundation in pathology and AI is rooted in its proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in digital pathology with an industry leading technology portfolio. Founded in 2017, Paige has developed and deployed several AI applications, including the first FDA-cleared AI application in pathology, allowin

    8/22/25 9:20:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus to Report Second Quarter 2025 Financial Results on August 8

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter of 2025 on Friday, August 8, 2025. The company will hold the earnings conference call at 8:00 a.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 7005219 Domestic Dial-in Number: (800) 715-9871 International Dial-in Numbe

    7/22/25 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus Reports First Quarter 2025 Results

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025. Revenue increased 75.4% year-over-year to $255.7 million in the first quarter of 2025 Quarterly gross profit increased 99.8% year-over-year, reaching $155.2 million with continued gross margin improvement in both Genomics and Data and services Announced multi-year, strategic collaborations with AstraZeneca and Pathos to work together to build the largest multimodal foundation model in oncology, resulting in additional $200.0 million in data licensing and model development fees over the next

    5/6/25 4:01:00 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Tempus AI with a new price target

    BTIG Research initiated coverage of Tempus AI with a rating of Buy and set a new price target of $60.00

    4/21/25 8:39:11 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus AI downgraded by Analyst with a new price target

    Analyst downgraded Tempus AI from Overweight to Neutral and set a new price target of $55.00 from $50.00 previously

    2/25/25 7:14:46 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus AI downgraded by William Blair

    William Blair downgraded Tempus AI from Outperform to Mkt Perform

    2/12/25 7:11:34 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Leonsis Theodore sold $3,075,600 worth of shares (44,000 units at $69.90) (SEC Form 4)

    4/A - Tempus AI, Inc. (0001717115) (Issuer)

    8/21/25 4:15:23 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    EVP and General Counsel Polovin Andrew sold $402,982 worth of shares (5,398 units at $74.65), decreasing direct ownership by 4% to 132,056 units (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    8/21/25 4:15:26 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    CEO and Chairman Lefkofsky Eric P sold $1,303,307 worth of shares (17,458 units at $74.65), decreasing direct ownership by 0.86% to 2,020,042 units (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    8/21/25 4:15:21 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology